Vivesto AB – LSE:0N4A.L

Vivesto AB stock price today

SEK 2.719
+2.44
+905.18%
Financial Health
0
1
2
3
4
5
6
7
8
9

Vivesto AB stock price monthly change

-29.06%
month

Vivesto AB stock price quarterly change

-29.06%
quarter

Vivesto AB stock price yearly change

+26.34%
year

Vivesto AB key metrics

Market Cap
 145.54M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -0.24
Revenue
 N/A
EBITDA
 -81.18M
Income
 -128.74M
Revenue Q/Q
 222.71%
Revenue Y/Y
 117.50%
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Vivesto AB stock price history

Vivesto AB stock forecast

Vivesto AB financial statements

Profit Margin

Vivesto AB (LSE:0N4A.L): Profit margin
Mar 2023 0 -20.42M
Jun 2023 0 -28.17M
Sep 2023 77K -15.78M -20498.7%
Dec 2023 6.53M -64.36M -984.85%
0N4A.L income statement history

Vivesto AB Financials Estimate

Vivesto AB (LSE:0N4A.L): Analyst Estimates
2025 24M -156.03M -650.14%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Vivesto AB (LSE:0N4A.L): Debt to assets
Mar 2023 330328000 25.34M 7.67%
Jun 2023 306932000 30.13M 9.82%
Sep 2023 283481000 22.31M 7.87%
Dec 2023 220673000 22.87M 10.37%
0N4A.L balance sheet history

Cash Flow

Vivesto AB (LSE:0N4A.L): Cash Flow
Mar 2023 -23.26M 19.78M -1.03M
Jun 2023 -16.48M 15.76M -885K
Sep 2023 -18.70M 20.25M -886K
Dec 2023 -10.28M 7.92M 2.80M
0N4A.L cash flow history

Vivesto AB alternative data

Vivesto AB
Employees

Vivesto AB (LSE:0N4A.L): Employee count
Aug 2023 20
Sep 2023 19
Oct 2023 19
Nov 2023 19
Dec 2023 14
Jan 2024 14
Feb 2024 14
Mar 2024 14
Apr 2024 14
May 2024 14
Jun 2024 14
Jul 2024 14

Vivesto AB other data

Frequently Asked Questions (FAQ)

  • What's the price of Vivesto AB stock today?

    One share of Vivesto AB stock can currently be purchased for approximately $2.72.

  • When is Vivesto AB's next earnings date?

    Unfortunately, Vivesto AB's (0N4A.L) next earnings date is currently unknown.

  • Does Vivesto AB pay dividends?

    No, Vivesto AB does not pay dividends.

  • How much money does Vivesto AB make?

    Vivesto AB has a market capitalization of 145.54M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 551.43% to 6.61M US dollars.

  • What is Vivesto AB's stock symbol?

    Vivesto AB is traded on the LSE under the ticker symbol "0N4A.L".

  • What is Vivesto AB's primary industry?

    Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.

  • How do i buy shares of Vivesto AB?

    Shares of Vivesto AB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Vivesto AB have?

    As Jul 2024, Vivesto AB employs 14 workers.

  • When Vivesto AB went public?

    Vivesto AB is publicly traded company for more then 20 years since IPO on 1 Jan 2005.

  • What is Vivesto AB's official website?

    The official website for Vivesto AB is vivesto.com.

  • How can i contact Vivesto AB?

    Vivesto AB can be reached via phone at +46 18 50 54 40.

Vivesto AB company profile:

Vivesto AB

vivesto.com
Exchange:

LSE

Full time employees:

4

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

+46 18 50 54 40
Gustav III:s Boulevard 46
Solna, 169 73

:
ISIN: SE0000722365
: